본문 바로가기
KERD
논문KCI 등재

Acute hepatitis C virus infection: clinical update and remaining challenges

Jia-Horng Kao|Chen-Hua Liu
대한간학회 (The korean Association for the Study of the Liver)|2023.07|Clinical and Molecular Hepatology|제29권 제3호|pp. 623-642

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Hepatitis C virusAcute infectionDirect-acting antiviral

초록

Acute hepatitis C virus (HCV) infection is a global health concern with substantial geographical variation in the incidence rate. People who have received unsafe medical procedures, used injection drugs, and lived with human immunodeficiency virus are reported to be most susceptible to acute HCV infection. The diagnosis of acute HCV infection is particularly challenging in immunocompromised, reinfected, and superinfected patients due to difficulty in detecting anti-HCV antibody seroconversion and HCV ribonucleic acid from a previously negative antibody response. With an excellent treatment effect on chronic HCV infection, recently, clinical trials investigating the benefit of direct-acting antivirals (DAAs) treatment for acute HCV infection have been conducted. Based on the results of cost-effectiveness analysis, DAAs should be initiated early in acute HCV infection prior to spontaneous viral clearance. Compared to the standard 8–12 week-course of DAAs for chronic HCV infection, DAAs treatment duration may be shortened to 6–8 weeks in acute HCV infection without compromising the efficacy. Standard DAA regimens provide comparable efficacy in treating HCV-reinfected patients and DAA-naïve ones. For cases contracting acute HCV infection from HCV-viremic liver transplant, a 12-week course of pangenotypic DAAs is suggested. While for cases contracting acute HCV infection from HCV-viremic non-liver solid organ transplants, a short course of prophylactic or pre-emptive DAAs is suggested. Currently, prophylactic HCV vaccines are unavailable. In addition to treatment scale-up for acute HCV infection, practice of universal precaution, harm reduction, safe sex, and vigilant surveillance after viral clearance remain critical in reducing HCV transmission.

Abstract

Acute hepatitis C virus (HCV) infection is a global health concern with substantial geographical variation in the incidence rate. People who have received unsafe medical procedures, used injection drugs, and lived with human immunodeficiency virus are reported to be most susceptible to acute HCV infection. The diagnosis of acute HCV infection is particularly challenging in immunocompromised, reinfected, and superinfected patients due to difficulty in detecting anti-HCV antibody seroconversion and HCV ribonucleic acid from a previously negative antibody response. With an excellent treatment effect on chronic HCV infection, recently, clinical trials investigating the benefit of direct-acting antivirals (DAAs) treatment for acute HCV infection have been conducted. Based on the results of cost-effectiveness analysis, DAAs should be initiated early in acute HCV infection prior to spontaneous viral clearance. Compared to the standard 8–12 week-course of DAAs for chronic HCV infection, DAAs treatment duration may be shortened to 6–8 weeks in acute HCV infection without compromising the efficacy. Standard DAA regimens provide comparable efficacy in treating HCV-reinfected patients and DAA-naïve ones. For cases contracting acute HCV infection from HCV-viremic liver transplant, a 12-week course of pangenotypic DAAs is suggested. While for cases contracting acute HCV infection from HCV-viremic non-liver solid organ transplants, a short course of prophylactic or pre-emptive DAAs is suggested. Currently, prophylactic HCV vaccines are unavailable. In addition to treatment scale-up for acute HCV infection, practice of universal precaution, harm reduction, safe sex, and vigilant surveillance after viral clearance remain critical in reducing HCV transmission.

참고문헌 (149)

  1. "Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018"[URL]
  2. Polaris Observatory HCV Collaborators, "Global change in hepatitis C virus prevalence and cascade of care between 2015and 2020 : a modelling study", Lancet Gastroenterol Hepatol, 7, pp.396~415 (2022)
  3. Lauer GM, "Hepatitis C virus infection", N Engl J Med, 345, pp.41~52 (2001)
  4. Liu CH, "Nanomedicines in the treatment of hepatitis C virus infection in Asian patients : optimizing use of peginterferon alfa", Int J Nanomedicine, 9, pp.2051~2067 (2014)
  5. Razavi H, "The present and future disease burden of hepatitis C virus(HCV)infection with today’s treatment paradigm", J Viral Hepat, 21(Suppl 1), pp.34~59 (2014)
  6. Thrift AP, "Global epidemiology and burden of HCV infection and HCV-related disease", Nat Rev Gastroenterol Hepatol, 14, pp.122~132 (2017)
  7. "Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021"[URL]
  8. "Global hepatitis report 2017"[URL]
  9. Pépin J, "Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010", PLoS One, 9, pp.e99677~ (2014)
  10. Pépin J, "Evolution of the global use of unsafe medical injections, 2000-2010", PLoS One, 8, pp.e80948~ (2013)
  11. Hauri AM, "The global burden of disease attributable to contaminated injections given in health care settings", Int J STD AIDS, 15, pp.7~16 (2004)
  12. Gore C, "Unnecessary injecting of medicines is still a major public health challenge globally", Trop Med Int Health, 18, pp.1157~1159 (2013)
  13. Mele A, "Prevention of hepatitis C in Italy : lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group", J Viral Hepat, 7, pp.30~35 (2000)
  14. Paez Jimenez A, "HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt", Gut, 59, pp.1554~1560 (2010)
  15. El Gaafary MM, "Surveillance of acute hepatitis C in Cairo, Egypt", J Med Virol, 76, pp.520~525 (2005)
  16. Jadoul M, "Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients", Kidney Int, 95, pp.939~947 (2019)
  17. Liu CH, "Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5", Hepatol Int, 16, pp.1001~1019 (2022)
  18. Fabrizi F, "Transmission of hepatitis C virus in dialysis units : a systematic review of reports on outbreaks", Int J Artif Organs, 38, pp.471~480 (2015)
  19. Degenhardt L, "Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B : findings from the Global Burden of Disease Study 2013", Lancet Infect Dis, 16, pp.1385~1398 (2016)
  20. Hajarizadeh B, "Epidemiology and natural history of HCV infection", Nat Rev Gastroenterol Hepatol, 10, pp.553~562 (2013)
  21. Martinello M, "Enhancing the detection and management of acute hepatitis C virus infection", Int J Drug Policy, 26, pp.899~910 (2015)
  22. Maher L, "Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia", Addiction, 101, pp.1499~1508 (2006)
  23. Hagan H, "Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection : the influence of time and place", Am J Epidemiol, 168, pp.1099~1109 (2008)
  24. Esmaeili A, "Higher incidence of HCV in females compared to males who inject drugs : A systematic review and metaanalysis", J Viral Hepat, 24, pp.117~127 (2017)
  25. Morris MD, "Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 Collaboration", Clin Infect Dis, 64, pp.860~869 (2017)
  26. Palmateer NE, "Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions", PLoS One, 9, pp.e104515~ (2014)
  27. van den Berg CH, "Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users", Eur J Epidemiol, 22, pp.183~193 (2007)
  28. Grebely J, "Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012", PLoS One, 9, pp.e97726~ (2014)
  29. "Hepatitis C Surveillance 2020"[URL]
  30. Pouget ER, "Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment", Addiction, 107, pp.1057~1065 (2012)
  31. van Santen DK, "Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014", J Hepatol, 67, pp.255~262 (2017)
  32. Jin F, "Prevalence and incidence of hepatitis C virus infection in men who have sex with men : a systematic review and metaanalysis", Lancet Gastroenterol Hepatol, 6, pp.39~56 (2021)
  33. Hagan H, "Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men", AIDS, 29, pp.2335~2345 (2015)
  34. Hasse B, "Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study", Clin Infect Dis, 51, pp.1314~1322 (2010)
  35. Apers L, "Risk factors for HCV acquisition among HIVpositive MSM in Belgium", J Acquir Immune Defic Syndr, 68, pp.585~593 (2015)
  36. Compton WM, "Substance use among men who have sex with men", N Engl J Med, 385, pp.352~356 (2021)
  37. Santantonio T, "Acute hepatitis C : current status and remaining challenges", J Hepatol, 49, pp.625~633 (2008)
  38. Kanda T, "Acute hepatitis C virus infection, 1986-2001 : a rare cause of fulminant hepatitis in Chiba, Japan", Hepatogastroenterology, 51, pp.556~558 (2004)
  39. Takano S, "Prospective assessment of incidence of fulminant hepatitis in post-transfusion hepatitis : a study of 504 cases", Dig Dis Sci, 39, pp.28~32 (1994)
  40. Kato T, "Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon", Gastroenterology, 125, pp.1808~1817 (2003)
  41. Wakita T, "Production of infectious hepatitis C virus in tissue culture from a cloned viral genome", Nat Med, 11, pp.791~796 (2005)
  42. Kanda T, "Chronic hepatitis C : Acute exacerbation and alanine aminotransferase flare", Viruses, 15, pp.183~ (2023)
  43. Micallef JM, "Spontaneous viral clearance following acute hepatitis C infection : a systematic review of longitudinal studies", J Viral Hepat, 13, pp.34~41 (2006)
  44. Grebely J, "The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection", Hepatology, 59, pp.109~120 (2014)
  45. van den Berg CH, "Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus(HCV)seroconverters from a community-based cohort", PLoS One, 6, pp.e27555~ (2011)
  46. Thomas DL, "The natural history of hepatitis C virus infection : host, viral, and environmental factors", JAMA, 284, pp.450~456 (2000)
  47. Monin MB, "Low spontaneous clearance rates of recently acquired hepatitis C virus in human immunodeficiency virus-positive men who have sex with men (PROBE-C study).", Clin Infect Dis, 76, pp.e607~e612 (2023)
  48. Soriano V, "Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe", J Infect Dis, 198, pp.1337~1344 (2008)
  49. Tillmann HL, "A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice", Gastroenterology, 139, pp.1586~1592 (2010)
  50. Thomson EC, "Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men", Gut, 60, pp.837~845 (2011)
  51. Thomas DL, "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus", Nature, 461, pp.798~801 (2009)
  52. Yang M, "Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection : a meta-analysis", J Gastroenterol Hepatol, 28, pp.1114~1121 (2013)
  53. Miri HH, "Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients : systematic review and metaanalysis", Arch Virol, 166, pp.2469~2478 (2021)
  54. Liu L, "Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution", Hepatology, 55, pp.1684~1691 (2012)
  55. Hajarizadeh B, "Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study", PLoS One, 10, pp.e0122232~ (2015)
  56. Gauthiez E, "A systematic review and meta-analysis of HCV clearance", Liver Int, 37, pp.1431~1445 (2017)
  57. Thimme R, "Determinants of viral clearance and persistence during acute hepatitis C virus infection", J Exp Med, 194, pp.1395~1406 (2001)
  58. Kuntzen T, "Viral sequence evolution in acute hepatitis C virus infection", J Virol, 81, pp.11658~11668 (2007)
  59. Schulze Zur Wiesch J, "Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence", J Exp Med, 209, pp.61~75 (2012)
  60. Harris HE, "Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?", J Viral Hepat, 14, pp.213~220 (2007)
  61. Farci P, "The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies", Science, 288, pp.339~344 (2000)
  62. Liu CH, "Selective transmission of hepatitis C virus quasi species through a needlestick accident in acute resolving hepatitis", Clin Infect Dis, 42, pp.1254~1259 (2006)
  63. Bull RA, "Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection", PLoS Pathog, 7, pp.e1002243~ (2011)
  64. Martinello M, "Management of acute HCV infection in the era of direct-acting antiviral therapy", Nat Rev Gastroenterol Hepatol, 15, pp.412~424 (2018)
  65. Layden TJ, "Hepatitis C kinetics : mathematical modeling of viral response to therapy", Semin Liver Dis, 20, pp.173~183 (2000)
  66. Santantonio T, "Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy", Clin Infect Dis, 43, pp.1154~1159 (2006)
  67. Hajarizadeh B, "Dynamics of HCV RNA levels during acute hepatitis C virus infection", J Med Virol, 86, pp.1722~1729 (2014)
  68. Vogel M, "Acute hepatitis C infection in HIV-positive patients", Curr Opin Infect Dis, 24, pp.1~6 (2011)
  69. Blackard JT, "Hepatitis C virus coinfection and superinfection", J Infect Dis, 195, pp.519~524 (2007)
  70. Okamoto H, "Superinfection of chimpanzees carrying hepatitis C virus of genotype II", 1b with that of genotype III, 1a, pp.Hepatology, 1994[DOI]
  71. Herring BL, "Frequent hepatitis C virus superinfection in injection drug users", J Infect Dis, 190, pp.1396~1403 (2004)
  72. Widell A, "Hepatitis C superinfection in hepatitis C virus(HCV)-infected patients transplanted with an HCV-infected kidney", Transplantation, 60, pp.642~647 (1995)
  73. Lai ME, "Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children", Lancet, 343, pp.388~390 (1994)
  74. Kao JH, "Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis", Gastroenterology, 105, pp.583~587 (1993)
  75. Kao JH, "Superinfection by homotypic virus in hepatitis C virus carriers : studies on patients with post-transfusion hepatitis", J Med Virol, 50, pp.303~308 (1996)
  76. Kao JH, "Mixed infections of hepatitis C virus as a factor in acute exacerbations of chronic type C hepatitis", J Infect Dis, 170, pp.1128~1133 (1994)
  77. Liaw YF, "Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection", J Gastroenterol, 37(Suppl 13), pp.65~68 (2002)
  78. Liaw YF, "Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection", Gastroenterology, 126, pp.1024~1029 (2004)
  79. Carithers RL Jr, "Diagnostic testing for hepatitis C", Semin Liver Dis, 20, pp.159~171 (2000)
  80. Schroeter M, "Prolonged time until seroconversion among hemodialysis patients : the need for HCV PCR", Intervirology, 48, pp.213~215 (2005)
  81. Thomson EC, "Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV", AIDS, 23, pp.89~93 (2009)
  82. Preiksaitis JK, "Serologic responses to hepatitis C virus in solid organ transplant recipients", Transplantation, 64, pp.1775~1780 (1997)
  83. Toyoda H, "Changes in hepatitis C virus(HCV)antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy", Clin Infect Dis, 40, pp.e49~e54 (2005)
  84. Santantonio T, "Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin", Hepatology, 59, pp.2101~2109 (2014)
  85. Martinello M, "Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection : the ATAHC II and DARE-C I studies", Antivir Ther, 21, pp.425~434 (2016)
  86. Corey KE, "Early treatment improves outcomes in acute hepatitis C virus infection : a meta-analysis", J Viral Hepat, 17, pp.201~207 (2010)
  87. Liu CH, "Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C", Clin Infect Dis, 51, pp.541~549 (2010)
  88. Fabrizi F, "Interferon therapy of acute hepatitis C in dialysis patients : meta-analysis", J Viral Hepat, 19, pp.784~791 (2012)
  89. Liu CH, "Peginterferon plus Ribavirin for HIV-infected patients with treatment-naïve acute or chronic HCV infection in Taiwan : A prospective cohort study", Sci Rep, 5, pp.17410~ (2015)
  90. Zhang B, "Treatment of acute hepatitis C infection with pegylated interferon and ribavirin in patients coinfected with human immunodeficiency virus : A systematic review and meta-analysis", Intervirology, 58, pp.242~249 (2015)
  91. Martinello M, "Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection : The DARE-C II study", Hepatology, 64, pp.1911~1921 (2016)
  92. Naggie S, "Sofosbuvir plus ribavirin without interferon for treatment of acute hepatitis C virus infection in HIV-1-infected individuals:SWIFT-C", Clin Infect Dis, 64, pp.1035~1042 (2017)
  93. Deterding K, "Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study", Lancet Infect Dis, 17, pp.215~222 (2017)
  94. Rockstroh JK, "Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection : an open-label, single-arm trial", Lancet Gastroenterol Hepatol, 2, pp.347~353 (2017)
  95. Naggie S, "Ledipasvir", Sofosbuvir for 8 weeks to treat acute hepatitis C virus infections in men with human immunodeficiency virus infections: Sofosbuvircontaining regimens without interferon for treatment of acute HCV in HIV-1 infected individuals, 2019, pp.69, 514~522
  96. Martinello M, "Shortened therapy of eight weeks with paritaprevir", ritonavir, J Viral Hepat, pp.2018, 25[DOI]
  97. Boerekamps A, "Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir(DAHHS2) : an open-label, multicentre, single-arm, phase 3b trial", Lancet Gastroenterol Hepatol, 4, pp.269~277 (2019)
  98. AASLD-IDSA HCV Guidance Panel, "Hepatitis C Guidance 2018Update : AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection", Clin Infect Dis, 67, pp.1477~1492 (2018)
  99. European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C : Final update of the series", J Hepatol, 73, pp.1170~1218 (2020)
  100. Martinello M, "Short-duration pan-genotypic therapy with Glecaprevir", Pibrentasvir for 6 weeks among people with recent hepatitis C viral infection, 2020, pp.72, 7~18
  101. Matthews GV, "Sofosbuvir", velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection, 2021, pp.75, 829~839
  102. Maasoumy B, "Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study).", J Hepatol, 77(Suppl 1), pp.S582~ (2022)
  103. Micallef S, "Acute hepatitis C infection with secondary liver injury successfully treated with sofosbuvir", velpatasvir combination, 2020, pp.81, 1~3
  104. Wu SH, "Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis Cinfected patient with hepatic decompensation", J Chin Med Assoc, 82, pp.595~598 (2019)
  105. Hatanaka T, "Ledipasvir and sofosbuvir for acute hepatitis C virus monoinfection associated with a high risk of acute liver failure", Intern Med, 58, pp.2969~2975 (2019)
  106. Li C, "A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection", Medicine(Baltimore), 97, pp.e0416~ (2018)
  107. Brancaccio G, "Treatment of acute hepatitis C with ledipasvir and sofosbuvir in patients with hematological malignancies allows early re-start of chemotherapy", Clin Gastroenterol Hepatol, 16, pp.977~978 (2018)
  108. Liu H, "Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis", Medicine(Baltimore), 95, pp.e5555~ (2016)
  109. Chromy D, "High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients", United European Gastroenterol J, 7, pp.507~516 (2019)
  110. Hussein NR, "Direct acting antiviral treatment for patients with end-stage kidney disease with acute HCV infection", Mediterr J Hematol Infect Dis, 11, pp.e2019034~ (2019)
  111. He YL, "Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis", Aliment Pharmacol Ther, 47, pp.526~532 (2018)
  112. Goel A, "Acute hepatitis C treatment in advanced renal failure using 8weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir", Nephrol Dial Transplant, 36, pp.1867~1871 (2021)
  113. Ji Q, "Safety and efficacy of grazoprevir", elbasvir in the treatment of acute hepatitis C in hemodialysis patients, 2022, pp.94, 675~682
  114. Simmons B, "Risk of late relapse or reinfection with hepatitis C Virus after achieving a sustained virological response : A systematic review and metaanalysis", Clin Infect Dis, 62, pp.683~694 (2016)
  115. Liu CH, "Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment", Aliment Pharmacol Ther, 55, pp.434~445 (2022)
  116. Liu CH, "Hepatitis C virus reinfection in people with HIV in Taiwan after achieving sustained virologic response with antiviral treatment : The RECUR study", Open Forum Infect Dis, 9, pp.ofac348~ (2022)
  117. Hosseini-Hooshyar S, "Risk of hepatitis C reinfection following successful therapy among people living with HIV : a global systematic review, meta-analysis, and meta-regression", Lancet HIV, 9, pp.e414~e427 (2022)
  118. Hajarizadeh B, "Hepatitis C reinfection after successful antiviral treatment among people who inject drugs : A metaanalysis", J Hepatol, 72, pp.643~657 (2020)
  119. Carson JM, "National trends in retreatment of HCV due to reinfection or treatment failure in Australia", J Hepatol, 78, pp.260~270 (2023)
  120. Carson JM, "Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort", Int J Drug Policy, 96, pp.103422~ (2021)
  121. Liu CH, "Sofosbuvir", velpatasvir or glecaprevir, Adv Dig Med, pp.2023, 10[DOI]
  122. Weinfurtner K, "Hepatitis C viraemic organs in solid organ transplantation", J Hepatol, 74, pp.716~733 (2021)
  123. Zahid MN, "Transplantation of organs from hepatitis C viruspositive donors under direct-acting antiviral regimens", J Clin Med, 11, pp.770~ (2022)
  124. Liu CH, "Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir", J Formos Med Assoc, 116, pp.407~409 (2017)
  125. Raasikh T, "Systematic review : hepatitis C viraemic allografts to hepatitis C-negative recipients in solid organ transplantation", Aliment Pharmacol Ther, 54, pp.571~582 (2021)
  126. McLean RC, "Transplanting hepatitis C virus-infected hearts into uninfected recipients : A single-arm trial", Am J Transplant, 19, pp.2533~2542 (2019)
  127. Bethea ED, "Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation : an open-label study", Lancet Gastroenterol Hepatol, 4, pp.771~780 (2019)
  128. Reyentovich A, "Outcomes of the treatment with Glecaprevir", Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors, 2020, pp.34, e13989~
  129. Smith DE, "Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors", Semin Thorac Cardiovasc Surg, 33, pp.407~415 (2021)
  130. Woolley AE, "Heart and lung transplants from HCV-infected donors to uninfected recipients", N Engl J Med, 380, pp.1606~1617 (2019)
  131. Cypel M, "Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors : an open-label, single-centre, pilot trial", Lancet Respir Med, 8, pp.192~201 (2020)
  132. Bethea E, "Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients : Implications for therapeutic planning", Am J Transplant, 20, pp.1619~1628 (2020)
  133. Terrault NA, "Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors", Hepatology, 73, pp.2110~2123 (2021)
  134. Kwong AJ, "Liver transplantation for hepatitis C virus(HCV)nonviremic recipients with HCV viremic donors", Am J Transplant, 19, pp.1380~1387 (2019)
  135. Goldberg DS, "Trial of transplantation of HCV-infected kidneys into uninfected recipients", N Engl J Med, 376, pp.2394~2395 (2017)
  136. Reese PP, "Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients : A single-group trial", Ann Intern Med, 169, pp.273~281 (2018)
  137. Durand CM, "Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients : An open-label nonrandomized trial", Ann Intern Med, 168, pp.533~540 (2018)
  138. Durand CM, "Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis C-viremic donors to hepatitis C-negative recipients : An open-label nonrandomized study", Ann Intern Med, 174, pp.137~138 (2021)
  139. Sise ME, "Multicenter study to transplant hepatitis Cinfected kidneys(MYTHIC) : An open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection", J Am Soc Nephrol, 31, pp.2678~2687 (2020)
  140. Gupta G, "Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants", Am J Transplant, 21, pp.3734~3742 (2021)
  141. Chen R, "Sofosbuvir", velpatasvir prophylaxis for 12 weeks in hepatitis C virus(HCV)-negative recipients receiving kidney transplantation from HCV-positive donors, 2021, pp.26, e933313~
  142. Feld JJ, "Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCVinfected donors : a phase 3, single-centre, open-label study", Lancet Gastroenterol Hepatol, 5, pp.649~657 (2020)
  143. Bethea ED, "Should we treat acute hepatitis C? A decision and cost-effectiveness analysis", Hepatology, 67, pp.837~846 (2018)
  144. "HCV guidance: recommendations for testing, managing, and treating hepatitis C"[URL]
  145. Naggie S, "Hepatitis C virus postexposure prophylaxis in the healthcare worker : Why direct-acting antivirals don’t change a thing", Clin Infect Dis, 64, pp.92~99 (2017)
  146. Liu CH, "Last mile to microelimination of hepatitis C virus infection among people living with human immunodeficiency virus", Clin Infect Dis, 73, pp.e2172~e2174 (2021)
  147. Frey SE, "Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults", Vaccine, 28, pp.6367~6373 (2010)
  148. Page K, "Randomized trial of a vaccine regimen to prevent chronic HCV infection", N Engl J Med, 384, pp.541~549 (2021)
  149. Donnison T, "A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice", Hepatology, 76, pp.1190~1202 (2022)

관련 논문AI추천

Predictors of spontaneous viral clearance and outcomes of acute hepatitis C김영남, 송병철, 조유경대한간학회 · Clinical and Molecular Hepatology2014 · 제20권 제4호Current and future strategies for the treatment of chronic hepatitis COmar Alshuwaykh, Paul Y. Kwo대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapyChung-Feng Huang, Ming-Lung Yu대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제3호Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisNobuyuki Toshikuni거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제3호Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failureAlessio Aghemo, Maria Corina Plaz Torres, Tommaso Lorenzo Parigi대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제4호Discussion on critical points for a tailored therapy to cure hepatitis C virus infectionAlfredo Focà, Angela Quirino, Carlo Torti, Chiara Costa, Giorgio Settimo Barreca, Giovanni Matera, Luisa Galati, Maria Carla Liberto, Maria Mazzitelli, Nadia Marascio, Vincenzo Pisani대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제1호

이 간행물의 다른 논문 (26건)

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer AssociationHyunchul Rhim, 김경민, Jin Woo Choi, Hee Ho Chu, Jung Suk Oh, In Joon Lee, Dong Hyeon Lee, Byung Chan Lee, Yuri Cho, Han Ah Lee, Dongho Hyun, Hoon Kwon, Kun Yung Kimpp. 521-541KASL clinical practice guidelines for management of autoimmune hepatitis 2022The Korean Association for the Study of the Liver (KASL)pp. 542-592Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversityTakumi Kawaguchi, Tomotake Shirono, Hideki Iwamoto, Takashi Niizeki, Shigeo Shimosepp. 593-604Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infectionChih-Lin Lin, Jia-Horng Kaopp. 605-622A decade of liver organoids: Advances in disease modelingJunjun Ding, Chun-Fang Yang, Jian-Ying Sheng, Yue Liu, Yun-Shen Chanpp. 643-669
원문 보기